Genoxal 200 mg polvo para solución inyectable y para perfusión
Sponsors
Grupo Espanol De Leucemia Linfocitica Cronica, Autolus Limited, Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Conditions
Refractary or relapse Hodgkin T CD30+ lymphomaRefractary or relapse non-Hodgkin T CD30+ lymphoma.Relapsed or refractory B cell acute lymphoblastic leukaemiaRelapsed/refractory large B-cell non-Hodgkin lymphomaRichter´syndromeand follicular lymphomamantle cell lymphoma
Phase 1
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.
Active, not recruitingCTIS2024-512903-38-00
Start: 2021-12-01Target: 17Updated: 2025-12-17
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.
Not yet recruitingCTIS2024-515624-36-00
Target: 40Updated: 2025-08-29
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
Not yet recruitingCTIS2024-519790-19-00
Target: 40Updated: 2025-09-29